Standing Order
Vertex Pharmaceuticals Incorporated

Dashboard

Vertex Pharmaceuticals Incorporated

VRTXNASDAQ

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$131B
Price$516.3452w $366.54 – $557.96
Conviction5/ 5
Revenue (TTM)$12.6B
Revenue growth YoY+10.6%
P/E (trailing)29.7
Gross margin86.0%
Operating margin38.6%
Net margin34.9%
52w price change+15.9%
Next earningsNov 2, 2026

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Sep 21
    Trial initiationClinicalTrials.gov

    Phase 2a study (NCT07161037) of VX-407 in ADPKD patients with subset of PKD1 variants updated to ACTIVE_NOT_RECRUITING status.

  • Sep 21
    Trial initiationClinicalTrials.gov

    Vertex Phase 2/3 adaptive study of VX-147 in APOL1-mediated proteinuric kidney disease (NCT05312879) status recruiting as of 2026-09-21.

  • Sep 21
    Trial initiationClinicalTrials.gov

    Vertex initiates Phase 1 dose-escalation study of VX-581 in healthy participants (NCT07283770).

  • Sep 18
    Trial initiationClinicalTrials.gov

    Vertex initiates Phase 2/3 trial of povetacicept in primary membranous nephropathy (NCT07204275, recruiting).

  • Sep 16
    Trial initiationClinicalTrials.gov

    Phase 2a study NCT07161037 of VX-407 in ADPKD patients with subset of PKD1 variants updated to ACTIVE_NOT_RECRUITING status.

  • Sep 16
    Trial readoutClinicalTrials.gov

    CTX001 Phase 2/3 trial (NCT03745287) in severe sickle cell disease completed per ClinicalTrials.gov update.

  • Sep 11
    Trial initiationClinicalTrials.gov

    Vertex initiates Phase 2 trial (NCT07501702) of povetacicept in generalized myasthenia gravis; status recruiting.

  • Sep 10
    OtherClinicalTrials.gov

    Vertex updates NCT05791201 Phase 1/2 VX-264 Type 1 Diabetes trial status to ACTIVE_NOT_RECRUITING.

  • Sep 10
    Ownership changeSEC

    Form 4 insider trading filing on 2026-09-10

  • Sep 10
    OtherClinicalTrials.gov

    Phase 3 trial NCT05331183 status updated to ACTIVE_NOT_RECRUITING for long-term ELX/TEZ/IVA safety/efficacy in non-F508del subjects.

  • Sep 10
    OtherClinicalTrials.gov

    Vertex updates phase 3 long-term safety/efficacy study NCT05444257 for VX-121 combo; status ACTIVE_NOT_RECRUITING as of 2026-09-10.

  • Sep 10
    Trial initiationClinicalTrials.gov

    Phase 1 relative bioavailability study of VX-581 tablet formulation listed as not yet recruiting (NCT07813039)

  • Sep 9
    OtherClinicalTrials.gov

    Vertex updates ClinicalTrials.gov for NCT06747572 (PKD1 gene variants in ADPKD); status ACTIVE_NOT_RECRUITING as of 2026-09-09

  • Sep 9
    Trial readoutClinicalTrials.gov

    Phase 1 trial NCT07378865 evaluating suzetrigine excretion into breast milk completed.

  • Sep 9
    Trial initiationClinicalTrials.gov

    ClinicalTrials.gov update: NCT05312879 Phase 2/3 adaptive study of VX-147 in APOL1-mediated proteinuric kidney disease status RECRUITING.

  • Sep 8
    Trial initiationClinicalTrials.gov

    Vertex Phase 3 open-label study of povetacicept in IgA nephropathy (NCT07807995) status not yet recruiting.

  • Sep 8
    Trial readoutClinicalTrials.gov

    Phase 1/2 VX-522 CF trial (NCT05668741) status updated to active, not recruiting.

  • Sep 4
    Trial initiationClinicalTrials.gov

    Vertex initiates Phase 2 trial (NCT07501702) of povetacicept in generalized myasthenia gravis; status recruiting

  • Sep 3
    OtherClinicalTrials.gov

    Phase 3 trial NCT06696443 evaluating long-term safety/effectiveness of suzetrigine in painful DPN updated to ACTIVE_NOT_RECRUITING (sponsor: Vertex).

  • Sep 2
    Trial initiationClinicalTrials.gov

    Vertex initiates Phase 2/3 trial of povetacicept in primary membranous nephropathy (NCT07204275, recruiting).

Not financial advice — research and opinion only. Disclosures